Menotropins: Physiology and What Research Reports

What Menotropins Are

Menotropins — commonly abbreviated hMG, for human menopausal gonadotropin — are gonadotropin preparations that carry both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity. They are extracted and purified from the urine of postmenopausal women, in whom circulating gonadotropins are naturally elevated because the ovaries no longer provide negative feedback to the pituitary. Because menotropins are large glycoprotein hormones rather than short synthetic chains, they sit at the edge of what most readers mean by "peptide," but they appear constantly in the same literature as GnRH agonists and antagonists, which are peptides.

Potency is expressed in international units of FSH and LH activity rather than in milligrams of protein, because the preparations are biological extracts standardised by bioassay. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medication, hormone therapy or fertility treatment.

The Underlying Physiology

The hormones that menotropins supply are normally produced by gonadotroph cells in the anterior pituitary gland, under pulsatile control from gonadotropin-releasing hormone (GnRH) released by the hypothalamus. FSH and LH are heterodimers: each shares a common alpha subunit and carries a distinct beta subunit that determines receptor specificity.

What the two activities do

• FSH activity acts on granulosa cells in the ovary, supporting recruitment and growth of antral follicles, and on Sertoli cells in the testis, supporting spermatogenesis.
• LH activity acts on theca cells and, later, on the mature follicle and corpus luteum; in the testis it acts on Leydig cells and drives testosterone production.
• Together, the two hormones underpin the classic two-cell, two-gonadotropin model of ovarian steroidogenesis, in which theca cells supply androgen precursors that granulosa cells aromatise to oestradiol.

Exogenous menotropins bypass the hypothalamic–pituitary step and stimulate the gonads directly. That is why they have been studied in settings where the goal is multi-follicular development, and why pituitary suppression with GnRH agonists or antagonists is often combined with them in assisted reproduction protocols described in the literature.

How Menotropins Are Measured and Studied

Research on menotropins is dominated by clinical fertility studies rather than by animal pharmacology. Typical measured endpoints in that literature include serum LH, FSH and oestradiol concentrations, follicle counts and diameters on ultrasound, oocyte yield, fertilisation and clinical pregnancy rates, early pregnancy loss, and complications such as ovarian hyperstimulation syndrome (OHSS). Because the preparations are biological extracts, batch standardisation and the ratio of FSH to LH activity are recurring methodological themes.

Comparative designs are common: menotropins versus purified or recombinant FSH, menotropins added to an existing stimulation regimen, or menotropins used inside different pituitary-suppression strategies. Observational and registry-style analyses have also been used to look at outcomes that are too infrequent to capture in a single small trial, such as congenital malformations.

What the Literature Reports

A 1991 review in Fertility and Sterility assessed the role of superovulation with menotropins in ovulatory infertility, that is, in women who were already ovulating rather than anovulatory (Fertility and Sterility, 1991). That review framed a question that has persisted in reproductive medicine: whether stimulating additional follicles adds value when ovulation itself is not the limiting factor.

More recently, researchers reported that patients experiencing early-onset low LH during GnRH antagonist cycles had a lower rate of early pregnancy loss when the cycles were supplemented with menotropin, in a 2019 analysis published in the Journal of the Formosan Medical Association (J Formos Med Assoc, 2019). That report is an example of the LH-activity question: antagonist protocols suppress endogenous LH, and the study examined whether restoring LH exposure through menotropin supplementation tracked with a different early-pregnancy outcome in that specific subgroup.

Menotropins Adverse Events: What Studies Report

The best-known hazard attached to gonadotropin stimulation in the published record is ovarian hyperstimulation syndrome. A 1988 Fertility and Sterility report described ovarian hyperstimulation syndrome occurring after D-Trp-6 luteinizing hormone-releasing hormone microcapsules were combined with menotropin for in vitro fertilization (Fertility and Sterility, 1988). OHSS is the exaggerated ovarian response that follows multi-follicular recruitment, and it is the reason stimulation protocols in the literature are monitored with serial oestradiol measurements and ultrasound.

A separate 1991 Fertility and Sterility paper examined early miscarriage and fetal malformations after induction of ovulation with clomiphene citrate and/or human menotropins, after in vitro fertilization, and after gamete intrafallopian transfer (Fertility and Sterility, 1991). Outcomes of that kind — pregnancy loss and congenital anomaly rates — are the endpoints most often raised when the safety of ovulation-induction agents is discussed, because they concern the offspring rather than only the treated patient. In the antagonist-cycle setting, the 2019 analysis reported early pregnancy loss as its primary outcome of interest in patients with early-onset low LH (J Formos Med Assoc, 2019).

Why the Term Turns Up in Peptide Reading

Readers encounter "menotropins" mainly through three doors. First, protocol descriptions: menotropins appear alongside GnRH agonists such as leuprolide and triptorelin, and alongside GnRH antagonists, all of which are genuine peptides. Second, terminology confusion: hMG, hCG, FSH and LH are distinct molecules with distinct receptor targets, and the abbreviations are frequently swapped in informal writing. Third, regulatory context: menotropin products are prescription pharmaceuticals approved for specific fertility indications and are not sold as research chemicals.

Limits of the Evidence

The cited literature here is small, is concentrated in assisted-reproduction populations, and spans more than three decades of changing laboratory technique, stimulation protocols and embryo-culture practice. Findings from an IVF cohort do not generalise to other populations, and observational comparisons cannot separate the effect of a drug from the characteristics of the patients who received it. None of the studies summarised on this page constitute guidance, and this page does not describe how any product is administered.

References

• Lower rate of early pregnancy loss in patients experiencing early-onset low LH in GnRH antagonist cycles supplemented with menotropin (Journal of the Formosan Medical Association, 2019)
• The role of superovulation with menotropins in ovulatory infertility: a review (Fertility and Sterility, 1991)
• Early miscarriage and fetal malformations after induction of ovulation (by clomiphene citrate and/or human menotropins), in vitro fertilization, and gamete intrafallopian transfer (Fertility and Sterility, 1991)
• Ovarian hyperstimulation syndrome following D-Trp-6 luteinizing hormone-releasing hormone microcapsules and menotropin for in vitro fertilization (Fertility and Sterility, 1988)